Trial Profile
A Double-blind, Placebo-controlled Study Evaluating the Pharmacodynamic Effects of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) on Hypothalamic-pituitary-adrenal Axis Function in Outpatients With Major Depressive Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 May 2012
Price :
$35
*
At a glance
- Drugs SSR 149415 (Primary)
- Indications Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Sanofi
- 29 May 2012 New trial record